Takeda et al. found that exogenous recombinant PlGF treatment not only improved the survival rate after MI and improved cardiac function but also significantly increased the number of CD31-positive cells and α-smooth muscle actin-positive vessels in the infarcted area and mobilized endothelial progenitor cells into the peripheral circulation [26]. Here, PECAM1 is linked to myocardial infarction.